الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 147 |  |  |
| | | from | 147 | | |
Abstract
Warts are caused by infection of the epidermis with HPV. Many people will experience infection with HPV at some time in their life. They have a significant impact on quality of life due to physical discomfort and embarrassment. The current main therapeutic options for warts include the destruction of visible lesions by physical or chemical methods and immunomodulating therapies. Intralesional antigen immunotherapy represents a promising therapeutic approach for the treatment of different types of warts, as it activates the immunologic response to HPV. Intralesional HBV vaccine has previously been reported to clear some cases of warts. It is assumed that HBV vaccine would work on the same basis of other antigens utilized in the intralesional immunotherapy for warts, which is stimulation of Th1 cytokine profile response such as IFN-γ, IL-2 and IL-12. Intralesional Candida antigen causes a cell-mediated immune response that can induce the regression not only of the treated wart, but frequently also warts at distant anatomic sites. Intralesional MMR immunotherapy results in stimulation a cellmediated immune response via recruitment of various immune cells (i.e., neutrophils, lymphocytes) and release of cytokines. Though it is injected intralesionally, the sensitization it produces may also result in clearance of non-injected distant warts.